U.S. FDA warns of ADHD drug Adderall shortage on Teva manufacturing delays
Oct 12 (Reuters) - The U.S. Food and Drug Administration said on Wednesday there was a shortage of Adderall, a treatment for attention deficit hyperactivity disorder, following intermittent manufacturing delays at Teva Pharmaceutical Industries Ltd (TEVA.TA).
Other Articles in this Edition
OHSU researchers sharpen estimate of true percentage of people with ADHD
U.S. FDA warns of ADHD drug Adderall shortage on Teva manufacturing delays
Annual Stimulant Prescriptions Have Doubled In Adolescents Since 2008
ADHD label may increase risk of self-harm in teens, study suggests
Understanding the Long-Term Clinical Course of Comorbid SUD and ADHD
ADHD Drugs Negatively Affect Bone Density
Human cells in a rat’s brain could shed light on autism and ADHD